UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One): Form 10-K Form 20-F Form 11-K [X] Form 10-Q Form N-SAR
For Period Ended: June 30, 1998 SEC File Number: 333-34765
Transition Report on Form 10-K CUSIP Number
Transition Report on Form 20-F 46600F 10 3
Transition Report on Form 11-K Transition Report on Form 10-Q Transition Report
on Form N-SAR For the Transition Period Ended:
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Full Name of Registrant:
IXION BIOTECHNOLOGY, INC
Former Name if Applicable:
N/A
Address of Principal Executive Office (Street and Number)
12085 RESEARCH DRIVE
City State and Zip Code
ALACHUA, FLORIDA 32615
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
(b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K or Form N-SAR or portion thereof, will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report of
X transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due
date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed period of time.
Necessary accounting information was not available at the time of filing.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Bruce Brashear, ESQ 352-336-0800
(2) Have all other periodic reports required under Section 13 of 15(d) of the
Securities and Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). Yes
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Name of Registrant as Specified in Charter: IXION BIOTECHNOLOGY, INC
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
/S/
Date: August 14, 1998 By: Weaver Gaines
President
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the state
is signed on behalf of the registrant by an authorized representative (other
than an executive officer), evidence of the representative's authority to sign
on behalf of the registrant shall be filed with the form.
